Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Standard
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. / Loges, Sonja; Mazzone, Massimiliano; Hohensinner, Philipp; Carmeliet, Peter.
In: CANCER CELL, Vol. 15, No. 3, 3, 2009, p. 167-170.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
AU - Loges, Sonja
AU - Mazzone, Massimiliano
AU - Hohensinner, Philipp
AU - Carmeliet, Peter
PY - 2009
Y1 - 2009
N2 - Clinical practice reveals that therapy with angiogenesis inhibitors often does not prolong survival of cancer patients for more than months, because tumors elicit evasive resistance. In this issue of Cancer Cell, two papers report that VEGF inhibitors reduce primary tumor growth but promote tumor invasiveness and metastasis. These perplexing findings help to explain resistance to these drugs but raise pertinent questions of how to best treat cancer patients with antiangiogenic medicine in the future. We discuss here how VEGF inhibitors can induce such divergent effects on primary tumor growth and metastasis.
AB - Clinical practice reveals that therapy with angiogenesis inhibitors often does not prolong survival of cancer patients for more than months, because tumors elicit evasive resistance. In this issue of Cancer Cell, two papers report that VEGF inhibitors reduce primary tumor growth but promote tumor invasiveness and metastasis. These perplexing findings help to explain resistance to these drugs but raise pertinent questions of how to best treat cancer patients with antiangiogenic medicine in the future. We discuss here how VEGF inhibitors can induce such divergent effects on primary tumor growth and metastasis.
M3 - SCORING: Zeitschriftenaufsatz
VL - 15
SP - 167
EP - 170
JO - CANCER CELL
JF - CANCER CELL
SN - 1535-6108
IS - 3
M1 - 3
ER -
